Skip to search formSkip to main contentSkip to account menu

Mulpleta

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Cablivi (caplacizumab-yhdp) for acquired thrombotic thrombocytopenic purpura; Egaten (triclabendazole) for fascioliasis; and… 
2018
2018
Mulpleta (lusutrombopag) for thrombocytopenia; ajovy (fremenezumab-vfrm) for migraine; takhzyro (lanadelumab-flyo) for hereditary… 
2017
2017
Sarilumab (Kevzara) for moderately to severely active rheumatoid arthritis; valbenazine (Ingrezza), the first approval for…